These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27994747)

  • 1. Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.
    Guo L; Parker DL; Zang Y; Sweis RF; Liu W; Sherer EC; Buist N; Terebetski J; Kelly T; Bugianesi R; Priest BT; Dingley KH; Li X; Mitelman S; Salituro G; Trujillo ME; Pachanski M; Kirkland M; Powles MA; Eiermann GJ; Feng Y; Shang J; Howard AD; Ujjainwalla F; Sinz CJ; Debenham JS; Edmondson SD; Nargund RP; Hagmann WK; Li D
    ACS Med Chem Lett; 2016 Dec; 7(12):1107-1111. PubMed ID: 27994747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.
    Wilson JE; Kurukulasuriya R; Sinz C; Lombardo M; Bender K; Parker D; Sherer EC; Costa M; Dingley K; Li X; Mitelman S; Tong S; Bugianesi R; Ehrhardt A; Priest B; Ratliff K; Ujjainwalla F; Nargund R; Hagmann WK; Edmondson S
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2947-2951. PubMed ID: 27240550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies.
    Yu M; Lizarzaburu M; Motani A; Fu Z; Du X; Liu JJ; Jiao X; Lai S; Fan P; Fu A; Liu Q; Murakoshi M; Nara F; Oda K; Okuyama R; Reagan JD; Watanabe N; Yamazaki M; Xiong Y; Zhang Y; Zhuang R; Lin DC; Houze JB; Medina JC; Li L
    ACS Med Chem Lett; 2013 Sep; 4(9):829-34. PubMed ID: 24900757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential role of GPR142 in tryptophan-mediated enhancement of insulin secretion in obese and lean mice.
    Ueda Y; Iwakura H; Bando M; Doi A; Ariyasu H; Inaba H; Morita S; Akamizu T
    PLoS One; 2018; 13(6):e0198762. PubMed ID: 29889885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.
    Toda N; Hao X; Ogawa Y; Oda K; Yu M; Fu Z; Chen Y; Kim Y; Lizarzaburu M; Lively S; Lawlis S; Murakoshi M; Nara F; Watanabe N; Reagan JD; Tian H; Fu A; Motani A; Liu Q; Lin YJ; Zhuang R; Xiong Y; Fan P; Medina J; Li L; Izumi M; Okuyama R; Shibuya S
    ACS Med Chem Lett; 2013 Aug; 4(8):790-4. PubMed ID: 24900747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
    Du X; Kim YJ; Lai S; Chen X; Lizarzaburu M; Turcotte S; Fu Z; Liu Q; Zhang Y; Motani A; Oda K; Okuyama R; Nara F; Murakoshi M; Fu A; Reagan JD; Fan P; Xiong Y; Shen W; Li L; Houze J; Medina JC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6218-23. PubMed ID: 22926069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The functional impact of G protein-coupled receptor 142 (Gpr142) on pancreatic β-cell in rodent.
    Al-Amily IM; Dunér P; Groop L; Salehi A
    Pflugers Arch; 2019 Apr; 471(4):633-645. PubMed ID: 30767071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism.
    Lin HV; Efanov AM; Fang X; Beavers LS; Wang X; Wang J; Gonzalez Valcarcel IC; Ma T
    PLoS One; 2016; 11(6):e0157298. PubMed ID: 27322810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human.
    Liu LZ; Ma T; Zhou J; Long Hu Z; Jun Zhang X; Zhen Zhang H; Zeng M; Liu J; Li L; Jiang Y; Zou Z; Wang F; Zhang L; Xu J; Wang J; Xiao F; Fang X; Zou H; Efanov AM; Thomas MK; Lin HV; Chen J
    Bioorg Med Chem Lett; 2020 Mar; 30(5):126857. PubMed ID: 31982234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPR142 Agonists Stimulate Glucose-Dependent Insulin Secretion via Gq-Dependent Signaling.
    Wang J; Carrillo JJ; Lin HV
    PLoS One; 2016; 11(4):e0154452. PubMed ID: 27104960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into unbound-bound states of GPR142 receptor in a membrane-aqueous system using molecular dynamics simulations.
    Kaushik AC; Sahi S
    J Biomol Struct Dyn; 2018 May; 36(7):1788-1805. PubMed ID: 28571491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure Based Virtual Screening Studies to Identify Novel Potential Compounds for GPR142 and Their Relative Dynamic Analysis for Study of Type 2 Diabetes.
    Kaushik AC; Kumar S; Wei DQ; Sahi S
    Front Chem; 2018; 6():23. PubMed ID: 29492402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
    Lizarzaburu M; Turcotte S; Du X; Duquette J; Fu A; Houze J; Li L; Liu J; Murakoshi M; Oda K; Okuyama R; Nara F; Reagan J; Yu M; Medina JC
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5942-7. PubMed ID: 22884988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and pharmacological effects of a novel GPR142 antagonist.
    Murakoshi M; Kuwabara H; Nagasaki M; Xiong YM; Reagan JD; Maeda H; Nara F
    J Recept Signal Transduct Res; 2017 Jun; 37(3):290-296. PubMed ID: 27807998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
    Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
    Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromanol 293B, an inhibitor of KCNQ1 channels, enhances glucose-stimulated insulin secretion and increases glucagon-like peptide-1 level in mice.
    Liu L; Wang F; Lu H; Ren X; Zou J
    Islets; 2014; 6(4):e962386. PubMed ID: 25437377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncoupling protein 2 regulates daily rhythms of insulin secretion capacity in MIN6 cells and isolated islets from male mice.
    Seshadri N; Jonasson ME; Hunt KL; Xiang B; Cooper S; Wheeler MB; Dolinsky VW; Doucette CA
    Mol Metab; 2017 Jul; 6(7):760-769. PubMed ID: 28702331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of First-phase Insulin Secretion in Early Diagnosis of Thyroid Diabetes and Type 2 Diabetes Mellitus.
    Meng LH; Huang Y; Zhou J; Liang XH; Xian J; Li L; Qin YF
    Chin Med J (Engl); 2017 Apr; 130(7):798-804. PubMed ID: 28345543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homology modeling of FFA2 identifies novel agonists that potentiate insulin secretion.
    Villa SR; Mishra RK; Zapater JL; Priyadarshini M; Gilchrist A; Mancebo H; Schiltz GE; Layden BT
    J Investig Med; 2017 Dec; 65(8):1116-1124. PubMed ID: 28784695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist.
    Pasternak A; Feng Z; de Jesus R; Ye Z; He S; Dobbelaar P; Bradley SA; Chicchi GG; Tsao KL; Trusca D; Eiermann GJ; Li C; Feng Y; Wu M; Shao Q; Zhang BB; Nargund R; Mills SG; Howard AD; Yang L; Zhou YP
    ACS Med Chem Lett; 2012 Apr; 3(4):289-93. PubMed ID: 24900466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.